Endurance Bio Inc
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
Endurance Bio Inc. s a clinical stage biotech focusing on cell energy metabolism for the treatment of neurodegenerative, metabolic and other diseases. We develop oral small molecules T-168 (Phase 2) and T-621 (nonclinical) to upregulate PGC-1α, TFEB and TRPML1, resulting in improved mitochondrial function, lysosomal function, autophagy and cellular homeostasis.
We will start a placebo-controlled phase 2 trial of T-168 in Parkinson’s disease in 2025. In addition, we have an approved CTA for a phase 2 trial in ALS. Our plan also includes several studies with T-621 in various indications.
Upregulation of PGC-1α, TFEB and TRPML1 with our phase 2 stage compound T-168 has shown compelling results in preclinical models of neurodegeneration, inflammation, aging (frailty, muscle strength, body composition), sickle cell disease, and other diseases.
Delegates please note: Due to time constraints, we will respectfully decline meetings with CDMOs, CROs, consultants and other vendors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}